Laurie McWilliams, MD
Allergy & Immunology · Raleigh, NCNPI 1699942714
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $64,405 of the $84,762 with a category attached, or 76.0%. GSK accounts for 67.2% of it on its own, with 29 other manufacturers making up the rest.
Across 376 payments — averaging $225.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$57K
- Boehringer Ingelheim$10K
- Chiesi USA, Inc.$8K
- AstraZeneca$3K
- Genentech USA, Inc.$1K
- Regeneron Healthcare Solutions, Inc.$1K
- plus $4K from 24 others
Across 401 payments — averaging $183.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$72K
- Sanofi US Services Inc.$1K
What the payments were for
- Consulting fees$7,1748%
- Speaking & faculty fees$64,40576%
- Travel & lodging$3,9395%
- Food & beverage$8,96811%
- Education$2760%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 80 | $56,939 |
| Boehringer Ingelheim | 11 | $10,219 |
| Chiesi USA, Inc. | 8 | $8,070 |
| AstraZeneca | 34 | $3,071 |
| Genentech USA, Inc. | 9 | $1,494 |
| Regeneron Healthcare Solutions, Inc. | 49 | $1,046 |
| Amgen | 83 | $821 |
| Sanofi | 23 | $679 |
| Novartis | 8 | $289 |
| Grifols USA, LLC | 6 | $232 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $230 |
| CSL Behring | 7 | $211 |
| Sanofi-aventis U.S. LLC | 3 | $205 |
| Aimmune Therapeutics, Inc. | 2 | $190 |
| Pfizer | 8 | $162 |
| Galderma Laboratories, L.p. | 3 | $136 |
| Kaleo, Inc. | 8 | $124 |
| Genentech, Inc. | 2 | $124 |
| AbbVie | 6 | $123 |
| Blueprint Medicines Corporation | 1 | $107 |
| Alk-abello, Inc | 3 | $56 |
| Lilly USA, LLC | 2 | $46 |
| Optinose US, Inc. | 2 | $37 |
| Phadia US Inc. | 2 | $33 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $25 |
| Biocryst US Sales Co., LLC | 1 | $24 |
| Pharming Healthcare, Inc. | 1 | $20 |
| Philips North America LLC | 1 | $20 |
| Circassia Inc. | 1 | $19 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$84,762 in reported general payments places this provider in the 85th percentile of 140 allergy & immunology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 12 | $101,331 |
| Dupixent SyringeDupilumab | 17 | $99,971 |
| Dupixent PenDupilumab | 14 | $49,497 |
| XolairOmalizumab | 11 | $31,058 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $17,916 |
| Advair HfaFluticasone Propion/Salmeterol | 31 | $13,170 |
| Spiriva RespimatTiotropium Bromide | 12 | $9,724 |
| SymbicortBudesonide/Formoterol Fumarate | 36 | $8,862 |
| Epinephrine | 25 | $6,374 |
| Arnuity ElliptaFluticasone Furoate | 23 | $5,352 |
| Wixela InhubFluticasone Propion/Salmeterol | 41 | $4,734 |
| Qvar RedihalerBeclomethasone Dipropionate | 15 | $4,131 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 24 | $3,826 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 14 | $2,915 |
| Azelastine Hcl | 62 | $2,222 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra | $211 | $101,33112 claims |
| Genentech, Inc.Xolair | $124 | $31,05811 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $56,939 | $23,26847 claims |
| Boehringer IngelheimSpiriva Respimat | $10,219 | $9,72412 claims |
| AstraZenecaSymbicort | $3,071 | $8,86236 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 140 allergy & immunology providers in North Carolina.
Other allergy & immunology in Raleigh
- Karen DunnRaleigh$258K
- Jonathan RomeoRaleigh$230K
- Sonia BainsRaleigh$23K
- Gurvinder DeogunRaleigh$14K
- Craig LaforceRaleigh$14K
- Maureen PetersenRaleigh$13K
- Heather GutekunstRaleigh$12K
- Maeve OconnorCharlotte$2.2M
- Joel HartmanWinston Salem$749K
- Cristine RadojicicDurham$558K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.